TELEFLEX INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 211.1 USD | +1.85% |
|
+0.48% | -15.33% |
Financials (USD)
| Sales 2024 * | 3.09B | Sales 2025 * | 3.27B | Capitalization | 9.94B |
|---|---|---|---|---|---|
| Net income 2024 * | 365M | Net income 2025 * | 501M | EV / Sales 2024 * | 3.39 x |
| Net Debt 2024 * | 534M | Net cash position 2025 * | 34M | EV / Sales 2025 * | 3.04 x |
| P/E ratio 2024 * |
27.8
x | P/E ratio 2025 * |
20.3
x | Employees | 14,500 |
| Yield 2024 * |
0.65% | Yield 2025 * |
0.65% | Free-Float | 97.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Teleflex Incorporated
More recommendations
More press releases
More news
| 1 day | +1.85% | ||
| 1 week | +0.48% | ||
| Current month | -6.66% | ||
| 1 month | -4.45% | ||
| 3 months | -14.84% | ||
| 6 months | +12.48% | ||
| Current year | -15.33% |
1 week
205.26
212.56
1 month
205.26227.65
Current year
205.26256.85
1 year
177.63276.43
3 years
177.63449.38
5 years
177.63449.38
10 years
99.56449.38
| Managers | Title | Age | Since |
|---|---|---|---|
Liam Kelly
CEO | Chief Executive Officer | 57 | 08-12-31 |
Thomas Powell
DFI | Director of Finance/CFO | 62 | 11-07-31 |
Howard Cyr
CMP | Compliance Officer | - | 17-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrew Krakauer
BRD | Director/Board Member | 69 | 17-12-31 |
Stuart Randle
BRD | Director/Board Member | 64 | 08-12-31 |
John Heinmiller
BRD | Director/Board Member | 69 | 18-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.03% | 16 M€ | -6.73% | ||
| 0.73% | 8 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 211.1 | +1.85% | 284,357 |
| 24-04-22 | 207.3 | +0.34% | 329,746 |
| 24-04-19 | 206.6 | -0.40% | 416,411 |
| 24-04-18 | 207.4 | -0.44% | 154,319 |
| 24-04-17 | 208.3 | -0.86% | 170,359 |
Delayed Quote Nyse, April 23, 2024 at 04:00 pm EDT
More quotes
Teleflex Incorporated specialises in the designing, manufacturing and selling of single-use medical devices for hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. Products are sold under the brand names Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck®. Net sales break down by category of products as follows:
- interventional cardiology, radiology and urology products (26.5%);
- vascular access solutions (25.9%);
- surgical devices (12.5%);
- anesthesia products (11.9%);
- other (23.2%).
Net sales are distributed geographically as follows: the United States (61.8%), Europe (25.5%), Asia-Pacific (9.1%) and other (3.6%).
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
211.1
USD
Average target price
262.4
USD
Spread / Average Target
+24.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.33% | 9.94B | |
| -2.25% | 187B | |
| -1.32% | 108B | |
| -3.92% | 67.71B | |
| +7.99% | 53.07B | |
| +15.74% | 47.36B | |
| +6.01% | 39.73B | |
| +10.81% | 28.56B | |
| +2.34% | 26.55B | |
| +15.97% | 25.13B |
- Stock Market
- Equities
- TFX Stock
